You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 150 No. 8, October 25, 1952 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

EVALUATION OF RED CROSS GAMMA GLOBULIN AS A PROPHYLACTIC AGENT FOR POLIOMYELITIS

1. PLAN OF CONTROLLED FIELD TESTS AND RESULTS OF 1951 PILOT STUDY IN UTAH

William McD. Hammon, M.D., Dr.P.H.; Lewis L. Coriell, M.D., Ph.D.; Joseph Stokes, Jr., M.D.

J Am Med Assoc. 1952;150(8):739-749.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The principal purpose of the experiment described in this and subsequent papers of the series was to determine whether gamma globulin, as prepared for and furnished by the American National Red Cross for measles prophylaxis, would protect against the paralytic manifestations of poliomyelitis when administered in reasonable dosage before the onset of illness. A secondary purpose was to determine, if protection were afforded, the duration of protection in the dosage selected for the experiment. From this, based on half life studies of gamma globulin in the childhood age group, the dosage suitable for any period of protection desired could be calculated. Another secondary purpose was to determine whether gamma globulin would permit or interfere with inapparent or milder types of nonparalyzing clinical infection and the subsequent development of active immunity. This question had considerable significance, for if harmless infection and subsequent active immunity were prevented, gamma globulin would have a . . . [Full Text PDF of this Article]


Author Affiliations

Pittsburgh; Camden, N.J.; Philadelphia

From the Department of Epidemiology and Microbiology, Graduate School of Public Health, University of Pittsburgh; Director of Project, and Professor and Head of Department of Epidemiology and Microbiology (Dr. Hammon); Deputy Director of Project and Director, Camden Municipal Hospital for Contagious Diseases and Department of Pediatrics, School of Medicine, University of Pennsylvania (Dr. Coriell); Consultant of Project and Physician-in-Chief, The Children's Hospital of Philadelphia and Department of Pediatrics, School of Medicine, University of Pennsylvania (Dr. Stokes).


Footnotes

This study was aided by a grant from the National Foundation for Infantile Paralysis, Inc.

Owing to lack of space, acknowledgments to the organizations, employed personnel, and volunteers who participated in the study will appear only in the authors' reprints.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1952 American Medical Association. All Rights Reserved.